Equity in UC Care: Listening to Patients and Integrating Novel Therapies to Induce and Maintain Remission
August 29, 2023
August 29, 2024
This activity is jointly provided by Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC.
This activity is supported by an independent educational grant from Bristol Myers Squibb Company.
Date of Release/Expiration
This activity was released on August 29, 2023 and is valid until August 29, 2024. Requests for credit must be made no later than August 29, 2024.
- Physicians - maximum of 1.0 AMA PRA Category 1 Credit™
The target audience for this activity are gastroenterologists and NPs/PAs involved in management of patients with IBD.
Sphingosine-1-phosphate receptor (S1PR) modulators are a recently approved treatment option for patients with ulcerative colitis (UC). However, many patients who would benefit from these advances in treatment are not receiving them. Furthermore, patients from non-White racial and ethnic backgrounds experience worse outcomes from UC, and face barriers to care and treatment. Optimized management for UC necessitates an up-to-date understanding of the therapeutic landscape and an equitable approach to treatment decision-making and care.
Join expert gastroenterologists, Florence-Damilola Odufalu, MD and Raymond Keith Cross Jr., MD, MS who will discuss the role of sphingosine-1-phosphate (S1P) receptor modulators in inducing and maintaining remission for patients with moderate-to-severe UC, provide guidance on how these therapies can be effectively integrated into management plans, and share strategies to address the unique challenges faced during the care of patients with UC across different races and ethnicities.
After completing this activity, the participant should be better able to:
- Discuss the burden of UC with a focus on the impacts of race and ethnicity on UC prognosis and care access
- Identify the role of S1P receptor modulators to induce and maintain remission of UC
- Establish strategies to break down barriers to UC care access among people of various races and ethnicities
Florence-Damilola Odufalu, MD
Assistant Professor of Clinical Medicine
Keck School of Medicine of University of Southern California
Raymond Keith Cross Jr., MD, MS
Professor of Medicine
Director of the IBD Program
University of Maryland School of Medicine
Patient with Ulcerative Colitis
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Relevant Financial Relationship(s)
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
Instruction for Participaton and Credit:
Estimated Time to Complete
This activity should take approximately 60 minutes to complete.
Instruction to Receive Credit
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Course Viewing Requirements
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
For additional information about the accreditation of this activity, please visit https://partnersed.com.
For any technical issues or issues with your CME Certificate, please contact ImmunologyLive at 877-394-1306 or at [email protected].
Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.
In plain English, here is what we affirm:
- You can change your registration profile at any time from our “Profile” page
- To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at [email protected]
- You can end your association with PlatformQ Health at any time
- PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
- EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting [email protected] with the subject line “Data Request”